Document Detail

Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment.
MedLine Citation:
PMID:  21208578     Owner:  NLM     Status:  Publisher    
OBJECTIVE: Development of biomarkers for early detection of Alzheimer's disease (AD) is a major clinical research goal. On the basis of the hypothesis that cardiovascular risk factors contribute to the pathogenesis of AD, we investigated whether the cardiovascular risk markers midregional proadrenomedullin (MR-proADM) and midregional proatrial natriuretic peptide (MR-proANP) predict a major clinical milestone, ie, conversion from predementia mild cognitive impairment (MCI) to manifest AD. METHOD: A group of 134 MCI patients, among 137 originally prospectively recruited at the memory disorder clinic at Malmö University Hospital, Malmö, Sweden, between July 1998 and June 2001, was clinically followed for 4-6 years. We determined whether plasma concentrations of MR-proADM and MR-proANP at baseline predicted time to conversion from MCI to clinically diagnosed AD (DSM-III-R). MCI was diagnosed according to Petersen criteria. RESULTS: During follow-up, 41.8% of MCI patients remained cognitively stable, 42.5% converted to possible and probable AD, and 15.7% converted to other forms of dementia (MCI-other). MCI converters and MCI-other patients showed increased concentrations of MR-proANP and MR-proADM compared to the stable MCI patients (P = .0001). At a cutoff of 87 pmol/L, MR-proANP yielded a sensitivity of 73.7% and a specificity of 64.3% for predicting conversion to AD. The survival analysis showed that higher values of MR-proANP and MR-proADM were associated with progression to AD. In a multivariate Cox regression model including known risk factors, MR-proANP and MR-proADM remained independent risk factors for conversion to AD for patients below the age of 72 years. CONCLUSIONS: Our study shows that plasma concentrations of MR-proANP and MR-proADM have predictive value in the progression from predementia MCI to clinical AD. Sensitivity was particularly high, which may recommend this test for first-stage screening in patients at risk for AD.
Katharina Buerger; Olga Uspenskaya; Oliver Hartmann; Oskar Hansson; Lennart Minthon; Kaj Blennow; Hans-Juergen Moeller; Stefan J Teipel; Andrea Ernst; Andreas Bergmann; Harald Hampel
Related Documents :
3546718 - The hypoechoic normal tendon. a pitfall.
3192088 - Simulated superior oblique tendon sheath syndrome.
8857968 - Tear of the distal biceps tendon presenting as an antecubital mass: magnetic resonance ...
17326088 - Magnetic resonance findings of osteitis pubis.
21057608 - Mri-compatible pneumatic robot for transperineal prostate needle placement.
16861558 - Mucinous adenocarcinoma arising from fistula in ano: mri findings.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2010-11-2
Journal Detail:
Title:  The Journal of clinical psychiatry     Volume:  -     ISSN:  1555-2101     ISO Abbreviation:  -     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2011-1-6     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7801243     Medline TA:  J Clin Psychiatry     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© Copyright 2010 Physicians Postgraduate Press, Inc.
Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig-Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Is DSM-IV bereavement exclusion for major depression relevant to treatment response? A case-control,...
Next Document:  Reasons for antidepressant nonadherence among veterans treated in primary care clinics.